NEWTON, Mass., Aug. 17, 2017 -- MariMed Inc. (OTCQB:MRMD) reported its second quarter 2017 financials in its recently filed 10Q, which was highlighted by quarterly revenue growth that exceeded 100% for the 11th consecutive quarter. Revenue increased by 150.4% to a record $1,621,057 for the three months ended June 30, 2017 from $647,440 in the prior year’s period. Net income in the second quarter of 2017 increased to $504,805 versus $39,047 in the prior year’s period. These significant increases were primarily due to the company’s cannabis clients generating a robust 74% increase in their sales under MariMed’s management.
“MariMed has assisted licensed cannabis clients in five states in developing state of the art cultivation, production, and dispensing facilities,” stated Robert Fireman, CEO of MariMed Inc. “Under MariMed’s direction, these facilities are now generating ongoing revenue streams as they move beyond their initial start-up phases and truly begin to thrive. We’re seeing greater acceptance of cannabis nationwide, which is translating to more sales from patients being served by our medical cannabis clients. As more states implement medical and recreational legal cannabis programs, MariMed expects to have more opportunities to write winning license applications and, in turn, develop and manage the best facilities in the country.”
MariMed’s revenue for the six months ended June 30, 2017 increased 119.7% to $2,771,776 versus $1,261,896 in the prior year period. Net income swung from a loss of $17,561 for the six months ended June 30, 2016, to a profit of $614,191 for the first half of 2017.
“Our business model and best practices have been proven to be replicable and scalable,” noted Jon Levine, MariMed’s CFO. “Our margins are increasing, as expected, by economies of scale we are realizing with the growth of our clients’ businesses under MariMed’s managed services. We have medical cannabis facilities under development in Massachusetts and Maryland. As these facilities become fully operational in early 2018 and with the expansion of our Kalm Fusion™ branded licensing program, we expect to see ongoing improvements in our future results.”
MariMed’s full financial statement is available at https://www.sec.gov/.
About MariMed (formerly Worlds Online):
MariMed is a management advisory company in the medical cannabis industry, leading the industry in the design, development, operation, funding, and optimization of medical cannabis cultivation, production, and dispensary facilities. MariMed’s team has developed state-of-the-art, regulatory-compliant legal cannabis facilities in multiple states. These facilities are models of excellence in horticultural principals, cannabis production, product development, and dispensary operations. MariMed is on the forefront of precision-dosed cannabis medicine for the treatment of specific medical conditions. MariMed’s branded products, such as Kalm Fusion™, are being licensed and distributed in legal cannabis states across the country. For additional information, visit www.MarimedAdvisors.com
Forward-Looking Statements
This release contains certain forward-looking statements and information relating to MariMed Inc. (the “Company”) that are based on the current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, the Company. Such statements reflect the current views of the Company with respect to future events and are subject to certain assumptions, including those described in this release. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as “should,” “could,” “anticipate,” “believe,” “intend,” “plan,” “might,” “potentially” or “expect.” The Company does not intend to update these forward-looking statements.
Contacts: Business Development Jon Levine, CFO, MariMed 844-244-0200 [email protected] Investor Relations Ed McGregor/Jody Burfening, LHA [email protected] 212-838-3777 Media Relations Julie Shepherd, Accentuate PR [email protected] 847-275-3643


Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
Robinhood Expands Sports Event Contracts With Player Performance Wagers
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 



